Immunogenicity of licensed influenza A (H1N1) 2009 monovalent vaccines in HIV-infected children and youth

Journal of the Pediatric Infectious Diseases Society

Volumn 2, Issue 4, 2013, Pages 352-360

  Pass, Robert F ^a   Nachman, Sharon ^b   Flynn, Patricia M ^c   Muresan, Petronella ^d   Fenton, Terence ^d   Cunningham, Coleen K ^e   Borkowsky, William ^f   McAuley, James B ^g   Spector, Stephen A ^h,i   Petzold, Elizabeth ^j   Levy, Wende ^j   Siberry, George K ^k   Handelsman, Ed ^l   Jill Utech, L ^g   Weinberg, Adriana ^m  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^g RUSH UNIVERSITY MEDICAL CENTER   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ RADY CHILDREN'S HOSPITAL   (United States)

^j SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

^k EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^l NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^m UNIVERSITY OF COLORADO   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; HEMAGGLUTINATION INHIBITING ANTIBODY; INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; OSELTAMIVIR; VIRUS HEMAGGLUTININ; VIRUS RNA;

ADOLESCENT; ADULT; ANTIBODY RESPONSE; ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; FEMALE; FOLLOW UP; HEMAGGLUTINATION INHIBITION TEST; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISPANIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; INFANT; INFLUENZA A (H1N1); MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PROTEIN DETERMINATION; PROTEIN SYNTHESIS INHIBITION; YOUNG ADULT;

EID: 84940725835     PISSN: 20487193     EISSN: 20487207     Source Type: Journal    
DOI: 10.1093/jpids/pit040     Document Type: Article

References (35)

1. Perez-Padilla R, de la Rosa-Zamboni D, de Leon SP, et al. Pneumonia and respiratory failure from Swine-origin influenza A (H1N1) in Mexico. N Engl J Med 2009; 361:680-9.
2. ANZIC. Critical care services and 2009 H1N1 influenza in Australia and New Zealand. N Engl J Med 2009; 361:1925-34.
3. Presanis AM, De Angelis D, et al. Team TNYCSFI, The severity of pandemic H1N1 influenza in the United States from April to July 2009: A Bayesian analysis. PLoS Med 2009; 6:e1000207.
4. Hancock K, Veguilla V, Lu X, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009; 361:1945-52.
5. Atashili J, Kalilani L, Adimora AA. Efficacy and clinical effectiveness of influenza vaccines in HIV-infected individuals: a metaanalysis. BMC Infect Dis 2006; 6:138-43.
6. Klein MB, Lu Y, Delbalso L, et al. Influenza virus infection is a primary cause of febrile respiratory illness in HIV-infected adults, despite vaccination. Clin Infect Dis 2007; 45:234-40.
7. Kroon FP, van Dissel JT, de Jong JC, van Furth R. Antibody response to influenza, tetanus and pneumococcal vaccines in HIV-seropositive individuals in relation to the number of CD4+ lymphocytes. AIDS 1994; 8:469-76.
8. Kunisaki KM, Janoff EN. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. The Lancet Infect Dis 2009; 9:493-504.
9. Lin JC, Nichol KL. Excess mortality due to pneumonia or influenza during influenza seasons among persons with acquired immunodeficiency syndrome. Arch Intern Med 2001; 161:441-6.
10. Madhi SA, Ramasamy N, Besselar TG, Saloojee H, Klugman KP. Lower respirtory tract infections assoicated with influenza A and B viruses in an area with a high prevalence of pediatric human immunodeficiency type 1 infection. Pediatr Infect Dis J 2002; 21:291-7.
11. Malaspina A, Moir S, Orsega SM, et al. Compromised B cell responses to influenza vaccination in HIV-infected individuals. J Infect Dis 2005; 191:1442-50.
12. Weinberg A, Song LY, Walker R, et al. Anti-influenza serum and mucosal antibody responses after administration of live attenuated or inactivated influenza vaccines to HIV-infected children. J Acquir Immune Defic Syndr 2010; 55:189-96.
13. de Jong JC, Palache AM, Beyer WE, et al. Hemagglutinationinhibiting antibody to influenza virus. Developmental Biology (Basel) 2003; 115:63-73.
14. Center for Biologics Evaluation and Research. Guidance for industry: clinical data needed to support the licensure of pandemic influenza vaccines. Food and Drug Administration 2007:4-10.
15. Greenberg MD, Lai MH, Hartel GF, et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 2009; 361:2405-13.
16. Nolan T, McVernon J, Skeljo M, et al. Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in infants and children, a randomized trial. JAMA 2010; 301:37-46.
17. Clark TW, Pareek M, Hoschler K, et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009; 361:2424-35.
18. Arguedas A, Soley C, Lindert K. Responses to 2009 H1N1 vaccine in children 3 to 17 years of age. N Engl JMed 2010; 362:370-2.
19. Plennevaux E, Blatter M, Cornish MJ, et al. Influenza A (H1N1) 2009 two-dose immunization of US children: an observerblinded, randomized, placebo-controlled trial. Vaccine 2011; 29: 1569-75.
20. Waddington CS,Walker WT, Oeser C, et al. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomized, parallel group, multicentre study. BMJ 2010; 340:e2649.
21. Montoya CJ, Toro MF, Aguirre C, et al. Abnormal humoral immune response to influenza vaccination in pediatric type-1 human immunodeficiency virus infected patients receiving highly active antiretroviral therapy. Mem Inst Oswaldo Cruz 2007; 102:501-8.
22. Vigano A, Zuccotti GV, Pacei M, et al. Humoral and cellular response to influenza vaccine in HIV-infected children with full viroimmunologic response to antiretroviral therapy. J Acquir Immune Defic Syndr 2008; 48:289-96.
23. Kroon FP, van Dissel JT, de Jong JC, et al. Antibody response after influenza vaccination in HIV-infected individuals: a consecutive 3-year study. Vaccine 2000; 18:3040-9.
24. Cooper C, Thorne A, Klein MB, et al. Immunogenicity is not improved by increased antigen dose or booster dosing of seasonal influenza vaccine in a randomized trial of HIV infected adults. PLoS One 2011; 6:e17758.
25. Crum-Cianflone NF, Eberly LE, Dublessis D, et al. Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in an immunocompromised population: a prospective study comparing HIV-infected adults with HIV-uninfected adults. Clin Infect Dis 2011; 52:138-46.
26. CDC. 2009-2010 Influenza season week 20 ending May 22, 2010. FluView 2010.
27. Ohmit SE, Monto AS. Symptomatic predictors of influenza virus positivity in children during the influenza season. Clin Infect Dis 2006; 43:564-8.
28. Bryant PA, Tebruegge M, Papadakis G, et al. Clinical and microbiologic features associated with novel swine-origin influenza A pandemic 2009 (H1N1) virus in children, a prospective cohort study. Pediatr Infect Dis J 2010; 29:694-8.
29. Fabbiani M, Di Giambenedetto S, Michela S, et al. Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients. Vaccine 2011; 29:2836-9.
30. Bickel M, von Hentig N, Wieters I, et al. Immune response after two doses of the novel split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients. Clin Infect Dis 2011; 52:122-7.
31. Kajaste-Rudnitski A, Galli L, Nozza S, et al. Induction of protective antibody response by MF59-adjuvanted 2009 pandemic A/ H1N1v influenza vaccine in HIV-1-infected individuals. AIDS 2011; 25:177-83.
32. Carmona A, Omenaca F, Tejedor JC, et al. Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months. Vaccine 2010; 28:5837-44.
33. Roman F, Vaman T, Gerlach B, et al. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03a-adjuvant: preliminary report of an observer-blind, randomised trial. Vaccine 2010; 28:1740-5.
34. Durando P, Fenoglio D, Boschini A, et al. Safety and immunogenicity of two influenza virus subunit vaccines, with or without MF59 adjuvant, administered to human immunodeficiency virus type 1-seropositive and -seronegative adults. Clin Vaccine Immunol 2008; 15:253-9.
35. Flynn P, Nachman S, Muresan P, et al. Safety and immunogenicity of 2009 pandemic H1N1 influenza vaccination in perinatally HIV-1-infected children, adolescents, and young adults. J Infect Dis 2012; 206:421-30.